Royalty Pharma (RPRX) Non Operating Investment Income (2019 - 2025)

Royalty Pharma has disclosed Non Operating Investment Income across 7 years of filings, most recently posting -$1.0 million for Q4 2025.

• Non Operating Investment Income for Q4 2025 came in at -$1.0 million, up 88.89% year-over-year; the trailing twelve-month figure through Sep 2025 was -$8.0 million (down 366.67% YoY), and the FY2024 annual result was -$6.0 million, down 162.01% from the prior year.
• Non Operating Investment Income came in at -$1.0 million for Q4 2025 at Royalty Pharma, down from $4.0 million in the prior quarter.
• In the past five years, Non Operating Investment Income ranged from a high of $71.8 million in Q2 2022 to a low of -$17.0 million in Q3 2021.
• The 5-year median for Non Operating Investment Income is -$990000.0 (2022), against an average of $4.2 million.
• Peak annual rise in Non Operating Investment Income reached 3861.39% in 2022, while the deepest fall reached 920.83% in 2022.
• Royalty Pharma's Non Operating Investment Income stood at -$96000.0 in 2021, then tumbled by 920.83% to -$980000.0 in 2022, then plunged by 785.71% to -$8.7 million in 2023, then slipped by 3.69% to -$9.0 million in 2024, then jumped by 88.89% to -$1.0 million in 2025.
• The last three Non Operating Investment Income figures came in at -$1.0 million (Q4 2025), $4.0 million (Q3 2025), and -$2.0 million (Q2 2025), per Business Quant data.